SITC 2023 | Upcoming advancements in cellular therapies for prostate cancer

Russell Pachynski, MD, Washington University School of Medicine, St Louis, MO, outlines what’s on the horizon for cellular immunotherapies in prostate cancer, such as the PSCA-CAR-T trial (NCT03873805), which tests the efficacy of prostate stem cell antigen in CAR-T applications. Dr Pachynski identifies the challenge of age in prostate cancers: being that most patients are elderly and heavily pretreated, meaning that they are often less able to handle certain treatment regimes. He believes this will be important to address when selecting patients for intensive therapies. This interview took place at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.